Nizar M. Tannir

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera et al. · New England Journal of Medicine · 2018 · 4.6K citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard Escudier, Thomas Powles et al. · The Lancet Oncology · 2016 · 939 citations · Full text

Medicine, Oncology, Pharmacology +12

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12